IN2013MN02442A - - Google Patents

Download PDF

Info

Publication number
IN2013MN02442A
IN2013MN02442A IN2442MUN2013A IN2013MN02442A IN 2013MN02442 A IN2013MN02442 A IN 2013MN02442A IN 2442MUN2013 A IN2442MUN2013 A IN 2442MUN2013A IN 2013MN02442 A IN2013MN02442 A IN 2013MN02442A
Authority
IN
India
Prior art keywords
polypeptide
fusion proteins
relates
molecules
methods
Prior art date
Application number
Other languages
English (en)
Inventor
John C Timmer
Brendan P Eckelman
Grant B Guenther
Peter L Nguy
Henry Chan
Quinn Deveraux
Original Assignee
Inhibrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Llc filed Critical Inhibrx Llc
Publication of IN2013MN02442A publication Critical patent/IN2013MN02442A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IN2442MUN2013 2011-06-28 2012-06-28 IN2013MN02442A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161502052P 2011-06-28 2011-06-28
US201161565625P 2011-12-01 2011-12-01
US201261638168P 2012-04-25 2012-04-25
US201261638516P 2012-04-26 2012-04-26
PCT/US2012/044742 WO2013003649A2 (en) 2011-06-28 2012-06-28 Wap domain fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2013MN02442A true IN2013MN02442A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-12

Family

ID=47424808

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2442MUN2013 IN2013MN02442A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-06-28 2012-06-28

Country Status (12)

Country Link
US (2) US8986688B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2726093A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2014528913A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20140068861A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103946388A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2012275295B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112013033801A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2839622A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2013MN02442A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX356433B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2639526C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013003649A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012272636A1 (en) 2011-06-24 2013-05-02 Advent Bio Holdings Llc Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
JP2014523900A (ja) 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー セルピン融合ポリペプチド及びその使用方法
CN103946388A (zh) * 2011-06-28 2014-07-23 英伊布里克斯有限责任公司 Wap结构域融合多肽及其使用方法
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
US10478508B2 (en) * 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2969009B1 (en) * 2013-03-15 2018-11-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
CN103804484B (zh) * 2014-01-24 2016-03-16 南京必优康生物技术有限公司 一种网红细胞生长因子及其制备方法和应用
EP3709019A1 (en) * 2014-07-23 2020-09-16 Inova Diagnostics, Inc. Compositions and methods for the diagnosis of rheumatoid arthritis
EP3212290A4 (en) * 2014-10-27 2019-01-23 Inhibrx LP SERPINFUSION POLYPEPTIDES AND METHOD OF USE THEREOF
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
MX389750B (es) * 2015-10-01 2025-03-20 Kopfkino Ip Llc Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
WO2017192580A1 (en) * 2016-05-02 2017-11-09 The Regents Of The University Of California Novel fusion proteins for treating inflammatory diseases
BR112019023543A2 (pt) * 2017-05-10 2020-05-26 Albajuna Therapeutics, S.L. Derivados de proteína de fusão fc com alta atividade dual antiviral e imunomoduladora do hiv
US10839195B2 (en) * 2017-08-08 2020-11-17 Uchicago Argonne, Llc Machine learning technique to identify grains in polycrystalline materials samples
BR112021010433A2 (pt) 2018-12-06 2021-08-24 Cytomx Therapeutics, Inc. Substratos cliváveis de metaloprotease de matriz e de serina ou cisteína protease e métodos de uso destes
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
US11663494B2 (en) 2019-12-05 2023-05-30 Uchicago Argonne, Llc Systems and methods for hierarchical multi-objective optimization
CN110964094B (zh) * 2019-12-20 2021-11-02 华中科技大学 人源白细胞蛋白酶抑制因子及其重组制备与应用
US11651839B2 (en) 2020-03-02 2023-05-16 Uchicago Argonne, Llc Systems and methods for generating phase diagrams for metastable material states
US11710038B2 (en) 2020-04-13 2023-07-25 Uchicago Argonne, Llc Systems and methods for active learning from sparse training data
EP4204091A2 (en) * 2020-10-29 2023-07-05 Formycon AG Ace2 fusion proteins and uses thereof
WO2025083294A2 (en) * 2024-02-29 2025-04-24 Ageronix SA Aat-fc fusion protein

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2364471A1 (en) * 1999-03-01 2000-09-08 Human Genome Sciences, Inc. Human serpin proteins
AU2050501A (en) * 1999-12-01 2001-06-12 Human Genome Sciences, Inc. Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
EP1355942B1 (en) * 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
JP4336498B2 (ja) * 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2007531707A (ja) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
KR100775343B1 (ko) * 2003-11-13 2007-11-08 한미약품 주식회사 면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
US7901688B2 (en) 2004-08-03 2011-03-08 Transtech Pharma, Inc. Rage fusion proteins
US7399746B2 (en) * 2004-10-06 2008-07-15 Mcgill University Agents for wound healing
AU2006236439B2 (en) * 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1896503B1 (en) 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
EP1889908A4 (en) * 2005-06-03 2012-04-25 Mochida Pharm Co Ltd PROTEIN FUSED WITH ANTI-CD14 ANTIBODY
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2012819A2 (en) * 2006-03-30 2009-01-14 The Research Foundation Of the City university of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
EP2162472B1 (en) * 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
US8598315B2 (en) * 2007-10-02 2013-12-03 Research Foundation Of City University Of New York Protein transduction domains derived from secretory leukocyte protease inhibitor
AR064713A1 (es) * 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
SE533763C2 (sv) * 2009-05-04 2010-12-28 Lars Hammar Upphängningsanordning
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN103946388A (zh) 2011-06-28 2014-07-23 英伊布里克斯有限责任公司 Wap结构域融合多肽及其使用方法
JP2014523900A (ja) * 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー セルピン融合ポリペプチド及びその使用方法

Also Published As

Publication number Publication date
AU2012275295B2 (en) 2016-11-10
NZ619035A (en) 2015-07-31
CA2839622A1 (en) 2013-01-03
AU2012275295A1 (en) 2014-01-16
WO2013003649A3 (en) 2013-03-21
KR20140068861A (ko) 2014-06-09
AU2017200928A1 (en) 2017-03-02
US9914765B2 (en) 2018-03-13
WO2013003649A2 (en) 2013-01-03
CN103946388A (zh) 2014-07-23
JP2014528913A (ja) 2014-10-30
US8986688B2 (en) 2015-03-24
RU2014102585A (ru) 2015-08-10
EP2726093A2 (en) 2014-05-07
RU2639526C2 (ru) 2017-12-21
EP2726093A4 (en) 2015-08-19
MX2013015324A (es) 2014-05-01
MX356433B (es) 2018-05-29
US20130011399A1 (en) 2013-01-10
BR112013033801A2 (pt) 2017-12-19
US20150147324A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
IN2013MN02442A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2013MN02441A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
TN2012000518A1 (en) Serum albumin binding molecules
BR112019001108A2 (pt) usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
PH12019500596A1 (en) Recombinant binding proteins and their use
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
EA201691669A1 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
WO2012109624A3 (en) Monovalent and multivalent multispecific complexes and uses thereof
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
EP3546481A3 (en) Anti-interleukin 22 (il-22) antibody and uses thereof
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
WO2014144621A3 (en) Modified fc fusion proteins
WO2012122378A3 (en) Antibody-like proteins for therapeutic and diagnostic use
NZ724196A (en) Uti fusion proteins
MX365560B (es) Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes.